Alamar Biosciences, Inc. (ALMR) Stock Price & How to Invest

Alamar Biosciences builds tools for measuring proteins in blood and other biofluids at concentrations conventional immunoassays struggle to see. Its core technology, NULISA, pairs antibody capture with a sequencing readout to push sensitivity far below standard ELISA methods, and the ARGO HT system, launched commercially in January 2024, automates the workflow so a lab can run hundreds of samples across a multiplexed panel. The panels are where the recurring money is: NULISAseq Neuro 220 for neurodegeneration work, Inflammation 250, and the newer Immune 340 for translational immunology, plus an eMTBR-tau blood bioassay added to the neuro panel in 2026. Customers are academic labs, biotechs and pharma research groups, more than 300 of them across 25 countries, and the company was founded in 2018 by Yuling Luo, who previously built Advanced Cell Diagnostics.

The model is instruments first, consumables after, and the second quarter of 2026 showed that mix working. Revenue reached $29.4 million, up 82% year over year, but the split matters more than the total: instrument sales grew 35% to $7.8 million while consumables grew 147% to $15.5 million, which is what a maturing installed base is supposed to look like. Gross margin widened to 60% from 53%. The company is still spending ahead of that, with $31.2 million of operating expenses producing a $13.2 million quarterly net loss, funded by roughly $250 million of cash and short-term investments left over from the April IPO at $17 a share. Management guided full-year 2026 revenue to $116 million to $120 million, about 59% growth at the midpoint, and the stock rose roughly 31% on August 11, 2026 in response to the results and that first public guidance. At around $37 a share the market cap sits near $2.5 billion, which is roughly 20 times guided 2026 revenue net of cash.

Almost all of Alamar's revenue comes from research budgets, so academic grant funding, biotech financing conditions and pharma R&D cuts flow straight into orders, and instrument purchases are the first thing a squeezed lab defers. Competition is well capitalized: Olink sits inside Thermo Fisher, SomaScan inside Standard BioTools, and Quanterix, Bio-Techne and the mass-spectrometry vendors all sell into the same labs, which means sensitivity and cost per sample claims get tested constantly. The panels are sold for research rather than clinical diagnosis, so any move toward diagnostics would bring regulatory work and cost that is not in today's numbers. Valuation leaves little slack, with the shares near 20 times guided 2026 revenue while the company loses money each quarter, so a single soft guide can reprice the stock hard in either direction. The IPO was in April 2026 and typical lockup arrangements expire around six months after listing, which can put additional shares into a thinly traded float in the fourth quarter.

5 analysts publish price targets on ALMR, averaging $33.40 against a $36.57 price as of August 2026, or -8.7%. The published targets run from $31.00 to $35.00, a narrow spread, and the ratings split 4 buy, 1 hold, 0 sell. Over the last six months there have been 2 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ALMR forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Alamar Biosciences, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Consumable pull-through per instrument. Alamar reported average annual pull-through above $400,000 per instrument for 2025, and consumables grew 147% in the second quarter of 2026 against 35% instrument growth. The most optimistic published target, $35.00, assumes this works close to its best case.

The case against. Almost all of Alamar's revenue comes from research budgets, so academic grant funding, biotech financing conditions and pharma R&D cuts flow straight into orders, and instrument purchases are the first thing a squeezed lab defers. The most pessimistic target, $31.00, is roughly what ALMR is worth if this bites instead.

Read the full bull and bear case on ALMR, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Alamar Biosciences, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$100 million, with Q2 2026 at ~$29.4 million, up ~82% year over year
• 2026 revenue guidance: ~$116 million to $120 million, ~59% growth at the midpoint
• Gross margin (Q2 2026): ~60%, up from ~53% a year earlier
• Net loss (Q2 2026): ~$13.2 million, on ~$31.2 million of operating expenses (~$13.8 million R&D, ~$17.4 million SG&A)
• Cash and short-term investments: ~$250 million at June 30, 2026, against ~$313 million of stockholders' equity
• Market cap: ~$2.5 billion (~69 million shares near $37), roughly 23 times trailing revenue

There is no meaningful price to earnings ratio here because the company loses money, so the market is working off revenue multiples: about 23 times trailing sales, or closer to 20 times the 2026 guide once the cash balance is netted out. That is in the range life-science tools investors pay for a platform growing north of 50% with widening gross margin, and it assumes the consumable annuity keeps building. The IPO priced at $17 in April 2026 and opened at $22.60, so the shares have roughly doubled from the offer price in four months, most of that in a single 31% session after the second-quarter report.

Other names that sit close to ALMR: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get ALMR exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ALMR sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ALMR fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Alamar is an early, fast-growing razor-and-blade tools business already priced for several more years of that growth, so consumable pull-through per instrument is the figure that has to keep compounding.

Whether ALMR is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ALMR a buy or a sell?, and where the stock could go from here in the ALMR stock forecast.

For income investors, whether ALMR pays a dividend and how the payout looks is covered in does ALMR pay a dividend? And to weigh ALMR against a peer, read the full side-by-side comparisons: ALMR vs BRKR and ALMR vs TECH.